A carregar...
Publicação
Development of a U1 snRNA-adapted gene therapeutic strategy to correct 5’ splicing defects in lysosomal storage disorders
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.21 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Study aims: To overcome the pathogenic effect of two 5’ splice donor site (SDS) mutations diagnosed in LSDs patients, we have exploited the use of the antisense-U1 snRNA mediated therapeutic strategy to correct both 5’ SDS mutations that were reported in patients with Mucopolysaccharidosis type I (MPS I) (3) and Mucolipidosis III alpha/beta (ML III alpha/beta).
Descrição
Palavras-chave
Doenças Genéticas U1snRNA Therapy MPS I ML III alpha/beta Lysosomal Storage Disorders (LSDs)